Pay Less, Gain More: UHS Tops HCA Healthcare Stock
UHS is HCA Healthcare’s peer in Health Care Facilities industry that has:
1) Lower valuation (P/OpInc) compared to HCA Healthcare stock
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying UHS stock vs. HCA stock
Individual stocks swing but a balanced asset allocation doesn’t. Trefis’ Boston-based, wealth management partner blends strategy and discipline to smooth out market noise.
- Why The Dip In TEM Stock Is A Buying Window
- Can Pfizer Stock Outrun A $17B Revenue Void?
- Chevron Earnings: Upstream Strength Overcomes Downstream Accounting Headwinds
- What Is Happening With Arista Networks Stock?
- How Much Upside Can V Stock Deliver?
- Kyndryl Stock: Strong Cash Flow Poised for a Re-Rating?
Key Metrics Compared
| Metric | HCA | UHS |
|---|---|---|
| P/OpInc* | 10.1x | 7.5x |
| LTM OpInc Growth | 13.4% | 26.5% |
| 3Y Avg OpInc Growth | 9.8% | 23.5% |
| LTM Revenue Growth | 7.1% | 10.2% |
| 3Y Avg Revenue Growth | 7.9% | 8.7% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
But do these numbers tell the full story? Read Buy or Sell HCA Stock to see if HCA Healthcare still has an edge that holds up under the hood. As a quick background, HCA Healthcare (HCA) provides comprehensive healthcare services across 182 U.S. hospitals, including general, psychiatric, and rehabilitation care, specializing in inpatient, intensive, cardiac, diagnostic, and emergency services.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if HCA Healthcare stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for HCA Healthcare in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for HCA Healthcare would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | HCA | UHS |
|---|---|---|
| P/OpInc* | 6.4x | 6.6x |
| LTM OpInc Growth | 10.8% | 25.7% |
| 3Y Avg OpInc Growth | 8.9% | 19.1% |
| LTM Revenue Growth | 6.8% | 9.6% |
| 3Y Avg Revenue Growth | 7.6% | 8.1% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | HCA | UHS |
|---|---|---|
| P/S | 1.6x | 0.9x |
| Market Cap (Current) | $ 120.5 Bil | $ 14.6 Bil |
| LTM Revenue | $ 75.60 Bil | $ 16.99 Bil |
| LTM Opinc | $ 11.96 Bil | $ 1.95 Bil |
| LTM Op Margin | 15.8% | 11.5% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the its benchmark – a combination of S&P 500, Russell, and S&P midcap index.